Sumitomo Mitsui Trust Group Inc. Sells 773,708 Shares of Standard BioTools Inc. $LAB

Sumitomo Mitsui Trust Group Inc. cut its position in shares of Standard BioTools Inc. (NASDAQ:LAB) by 12.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,391,829 shares of the company’s stock after selling 773,708 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 1.41% of Standard BioTools worth $7,009,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. AQR Capital Management LLC increased its position in shares of Standard BioTools by 862.2% during the first quarter. AQR Capital Management LLC now owns 482,912 shares of the company’s stock valued at $522,000 after acquiring an additional 432,725 shares in the last quarter. Rhumbline Advisers raised its position in shares of Standard BioTools by 11.4% during the 1st quarter. Rhumbline Advisers now owns 412,761 shares of the company’s stock valued at $446,000 after purchasing an additional 42,247 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in shares of Standard BioTools by 67.0% during the 2nd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 45,297 shares of the company’s stock valued at $54,000 after buying an additional 18,178 shares in the last quarter. Savant Capital LLC boosted its holdings in Standard BioTools by 199.3% in the 2nd quarter. Savant Capital LLC now owns 56,957 shares of the company’s stock worth $68,000 after buying an additional 37,926 shares during the period. Finally, Geode Capital Management LLC increased its stake in Standard BioTools by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 7,441,134 shares of the company’s stock worth $8,931,000 after buying an additional 235,677 shares in the last quarter. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

LAB has been the topic of several research analyst reports. Zacks Research upgraded Standard BioTools to a “hold” rating in a research report on Thursday, December 11th. Wall Street Zen downgraded Standard BioTools from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 8th. TD Cowen dropped their price target on Standard BioTools from $1.55 to $1.35 and set a “hold” rating for the company in a research note on Wednesday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Standard BioTools in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $1.35.

Standard BioTools Stock Down 1.3%

Standard BioTools stock opened at $1.56 on Friday. The company has a market cap of $599.93 million, a price-to-earnings ratio of -4.59 and a beta of 1.26. The firm’s fifty day moving average is $1.41 and its 200 day moving average is $1.34. Standard BioTools Inc. has a 52-week low of $0.92 and a 52-week high of $1.89.

Insider Activity

In other Standard BioTools news, Director Casdin Partners Master Fund, L purchased 150,000 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was purchased at an average price of $1.45 per share, with a total value of $217,500.00. Following the acquisition, the director owned 72,100,000 shares in the company, valued at approximately $104,545,000. The trade was a 0.21% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In the last 90 days, insiders have bought 11,225,000 shares of company stock worth $14,408,250. 23.16% of the stock is currently owned by corporate insiders.

Standard BioTools Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.